1.	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2612-2277, NCT00122720
2.	Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia Phase: Phase IV Type: Health services research, Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR002455, EPOCAN4015, NCT00264108
3.	Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 04/Q1907/94, NCT00234143
4.	Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer Phase: Phase III, Phase II Type: Supportive care Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: 2005-005658-37, LM: 2612-3148, Ethical: 20060074, Data Protection: 2005-41-6015, NCT00381836
5.	Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Completed Age: 16 to 69 Sponsor: Other Protocol IDs: TJE0301, NCT00557817
6.	Anemia in Patients With a Non-Myeloid Malignancy Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20010101, UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982, NCT00038064
7.	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000333213, P30CA016042, UCLA-0306021, AMGEN-20030125, NCT00070382
8.	A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20010145, NCT00119613
9.	R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 66 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: LNH03-6B, NCT00144755
10.	AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040156, NCT00135317
11.	A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients Phase: Phase III Type: Supportive care Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: KRN321-SC/05-A54, NCT00344409
12.	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000593480, P30CA015083, MC04CC, NCI-2009-01226, 1713-05, MAYO-MC04CC, NCT00661999
13.	Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20010103, UCLA-0403046-01, AMGEN-20010103, NCT00091858
14.	A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: HEMMDS0001, NCT00230321
15.	Phase II Randomized Study of Darbepoetin alfa for the Treatment of Anemia in Patients With Nonmyeloid Malignancies Receiving Multiple Courses of Chemotherapy Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0111006, AMGEN-20010162, NCI-G02-2071, NCT00039247
16.	Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 60 and over Sponsor: NCI, Other Protocol IDs: CDR0000288830, MSKCC-02090, NCT00058422
17.	Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000350089, U10CA031946, CALGB-30303, NCT00077311
18.	Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia? Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 01/155A, NCT00039884
19.	Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer Phase: Phase II Type: Supportive care Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 20030204, NCT00095277
20.	Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040262, NCT00144131
21.	Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: jth_004, NCT00204633
22.	Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040232, NCT00239239
23.	ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040137, NCT00261313
24.	A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor Phase: Phase II Type: Supportive care Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: KRN321-SC/05-A55, NCT00359840
25.	A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20030207, UCLA-0404057-01, AMGEN-20030207, NCT00095264